Overview
This page compares Injective and GLM with live PEPS metrics. Rankings (#99 vs #271) and liquidity profiles differ, so traders often use them for distinct roles rather than as perfect substitutes.
Quick winners
Full comparison
| Metric | INJ | GLM |
|---|---|---|
| Price | $5.00 | $0.091600 |
| Market Cap | $490.41M | $91.43M |
| FDV | — | — |
| Volume 24h | $2.50M | $30,430.66 |
| Circulating Supply | — | — |
| Total Supply | — | — |
| Max Supply | — | — |
| Rank | 99.00 | 271.00 |
| Dominance | — | — |
| Liquidity | — | — |
| Volatility | +5.97% | +3.64% |
| ATH | — | — |
| ATL | — | — |
| ROI | — | — |
Performance
| Timeframe | INJ | GLM |
|---|---|---|
| 1H | — | — |
| 24H | +1.77% | -0.87% |
| 7D | — | — |
| 30D | — | — |
| 90D | — | — |
| 1Y | — | — |
| YTD | — | — |
| ALL | — | — |
Comparative chart
Technical indicators
| Indicator | INJ | GLM |
|---|---|---|
| RSI | 49.29 | 49.02 |
| MACD histogram | — | — |
| EMA20 | — | — |
| EMA50 | — | — |
| EMA100 | — | — |
| EMA200 | — | — |
| SMA50 | — | — |
| SMA200 | — | — |
| ATR | 0.29 | 67.35 |
| ADX | 12.19 | 21.33 |
| Support | 4.91 | 1,827.82 |
| Resistance | 5.07 | 1,960.30 |
| Trend | neutral | bearish |
| Momentum | — | 65.00 |
| Signal | neutral | neutral |
Automatic technical analysis
When RSI and trend disagree across Injective and GLM, expect choppy relative performance until one side reclaims a clear structure.
Fundamentals
| Metric | INJ | GLM |
|---|---|---|
| Consensus | — | — |
| Blockchain | — | — |
| TPS | — | — |
| Block time | — | — |
| Finality | — | — |
| Validators | — | — |
| Staking | — | — |
| TVL | — | — |
| Supply model | — | — |
| Inflation | — | — |
| Developer activity | 0.00 | — |
| Github activity | 118.00 | — |
| On-chain activity | — | — |
| Whale activity | — | — |
| Addresses | — | — |
| Gas fees | — | — |
Ecosystem
Injective
GLM
Pros and cons
Pros of Injective
- Market-cap scale on Injective may dampen some idiosyncratic shocks versus smaller peers.
- Injective typically benefits from deeper liquidity and broader market recognition inside the Top 300 set.
- Higher ranking for Injective can translate into tighter spreads on major venues.
- INJ often anchors narratives that attract sustained media and analyst coverage.
Cons of Injective
- Data gaps in niche fundamentals still apply — absence of a field is not confirmation.
- Indicator stacks on Injective may stay stretched longer than expected in strong trends.
- Regulatory or macro headlines can hit Injective harder simply because it is more visible.
Pros of GLM
- If technical momentum aligns, GLM may outperform on medium-term windows.
- Diversifying versus Injective with GLM can change portfolio factor exposure.
- PEPS tracking for GLM still includes AI score and level context for monitoring.
Cons of GLM
- Incomplete fundamental coverage can hide operational or tokenomic risks.
- Relative underperformance versus Injective can persist through entire market regimes.
- Weaker market-cap standing may leave GLM more exposed to liquidity droughts.
- Higher volatility on GLM cuts both ways and demands stricter risk limits.
Which looks stronger right now?
The “stronger” label here is descriptive, not predictive. Injective and GLM can alternate leadership as macro liquidity and narrative rotate.
AI summary
In about three hundred words of context: Injective (INJ) trades near $5.00 with a +1.77% day move, while GLM (GLM) is around $0.091600 (-0.87%). Volume leadership currently sits with Injective, and market-cap leadership with Injective. Technical trend labels read neutral vs bearish, with RSI near 49.29/49.02. Bottom line: use this page as a structured checklist, then open each coin page and related PEPS tools before acting. Nothing here is financial advice.
FAQ
Which is better, Injective or GLM?
“Better” depends on horizon and risk. Injective leads on market cap today, while Injective leads the 24h move — neither is a guarantee.
Which has more upside potential, INJ or GLM?
Higher-beta assets can move more in both directions. Use performance tables and volatility, not headlines, to judge potential ranges.
Which is less risky right now?
Lower volatility and deeper liquidity usually imply milder path risk, but crypto tails remain large for both Injective and GLM.
Which has stronger developer activity?
Check the fundamentals table for developer/github fields when populated. Missing values mean the feed has no reliable reading yet.
Which looks more decentralized?
Decentralization is multi-dimensional (validators, client diversity, token distribution). This page surfaces available consensus/validator fields without over-claiming.
Which has lower fees?
Fee comparisons belong to each network’s fee market. Where gas/fee metrics exist in fundamentals, compare them; otherwise verify on explorers.
Which is better for investing?
Investing choices need personal constraints. Use this comparison as research input, then size positions with an explicit invalidation plan.
Which is better for staking?
If staking fields are present, compare yield mechanics and lockups off-platform. Staking returns are not risk-free.
Which is more used day to day?
Volume, on-chain activity and ecosystem links are practical usage proxies. Injective currently leads traded volume on this snapshot.
Which has the better recent performance?
See the performance table across 1h through 1y. The 24h leader is Injective, but longer windows can disagree.